Schizophrenia Market Size, Share, and Industry Report [2031]
Schizophrenia Market Size, Share, and Industry Report [2031]
Segments - Schizophrenia Market by Types (Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, and Others), Diagnosis (Physical Examination, Psychiatric Evaluation, and Tests & Screenings), Treatments (First-generation Antipsychotics, Second-generation Antipsychotics, Third-generation Antipsychotics, Psychotherapies, and Other Therapeutic Drugs), Routes of Administrations (Injectables and Oral), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030
Upcoming
| Report ID :HC-4239
| 4.8 Rating
| 73 Reviews
| 170 Pages
| Format :
Report Description
The global schizophrenia market size was valued at around USD 7,666 million in 2021 and is anticipated to reach USD 11,056 million by 2030, expanding at a CAGR of around 4.1% during the forecast period, 2022 – 2030. The growth of the market is attributed to the rising cases of schizophrenia around the globe.
The World Health Organization (WHO) describes schizophrenia as substantial impairments in the way reality is perceived by individuals. It is considered as a chronic and serious mental disorder in which individuals interpret reality in abnormal way. It affects thoughts, behavior, and feelings of an individual. An individual suffering from schizophrenia had difficulties between reality and fantasy. Some of the symptoms of Schizophrenia includes delusions, hallucinations, social withdrawal, difficulty in paying attention, and others.
Psychiatrists and psychologists diagnose schizophrenia with blood tests, MRI scans, physical tests, psychiatric evaluations, and others. After the diagnosis, psychiatrists suggest methods of treatment for the disease. Individua suffering from schizophrenia require lifelong treatment. The treatment methods include different types of psychotherapies including cognitive behavior therapy, individual therapy, social skills training, and others, medication such as second-generation antipsychotics, and other therapeutic drugs. Early diagnosis and treatment aid individuals to get symptoms of the disease under control before any serious complications arise and to improve the long-term outlook.
Market Trends, Drivers, Restraints, and Opportunities
- Rapidly changing lifestyle is expected to drive the global schizophrenia market during the forecast period.
- Increasing consumption of alcohol, narcotics, and others is anticipated to boost the market in the coming years.
- Increasing expenditure and investments in mental health spurs the market.
- Surging chronic ailments around the globe are expected to drive the market during the projected period.
- Lack of awareness regarding schizophrenia in developing countries is anticipated to hamper the growth of the market during the forecast period.
- High cost of treatments for schizophrenia restrains the market.
- Growing demand for improved healthcare infrastructure and services offer growth opportunities to the key market players.
Scope of the Report
The report on the global schizophrenia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Schizophrenia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2021 |
|
Historic Data |
2019–2020 |
|
Forecast Period |
2022–2030 |
|
Segmentation |
Types (Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, and Others), Diagnosis (Physical Examination, Psychiatric Evaluation, and Tests & Screenings), Treatments (First-generation Antipsychotics, Second-generation Antipsychotics, Third-generation Antipsychotics, Psychotherapies, and Other Therapeutic Drugs), and Routes of Administrations (Injectables and Oral) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Mayo Foundation for Medical Education and Research (MFMER); Allergan, Plc; Novartis AG; PsychoGenics, Inc.; Merz Pharma GmbH & Co.; and Others |
Market Segment Insights
Paranoid schizophrenia drives the market
Based on types, the market is divided into catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. The paranoid schizophrenia segment is expected to boost the market during the forecast period, as it is considered as a common type of schizophrenia. Changing lifestyle, growing stress, and increasing cases of drug abuse aid in the expansion of the segment.
Psychiatric evaluation segment boosts the market
In terms of diagnosis, the market is segregated into physical examination, psychiatric evaluation, and tests & screenings. The psychiatric evaluation segment is projected to drive the market during the forecast period, as it is considered as a reliable method to diagnose schizophrenia. Through psychiatric evaluation, doctors observe patients for symptoms for schizophrenia such as hallucinations, delusions, catatonic behavior, disorganized speech, and negative symptoms such as lack of pleasure, withdrawal, diminished emotional expression, and others.
Second-generation antipsychotics segment holds a key market share
On the basis of treatments, the market is divided into first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs. The second-generation antipsychotics segment is estimated to expand at a significant pace during the forecast period, as they are considered to aid in curing some or all of the symptoms of schizophrenia. The second-generation antipsychotic drugs such as Risperdal (Risperidone), Seroquel (Quetiapine), Zyprexa (Olanzapine), Geodon (Ziprasidone), and others are commonly prescribed by doctors to treat schizophrenia.
Injectables segment expands rapidly
In terms of routes of administrations, the market is bifurcated into injectables and oral. The injectable segment is projected to fuel the market during the forecast period, owing to its high efficiency and lower chances of hospitalization. Continuous advancements in treatment methods aids in the expansion of the segment. The oral segment is anticipated to boost the market during the forecast period, as they are considered as the first-line of treatment for schizophrenia, and they are easily available.
North America dominates the market
Based on regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to register a significant CAGR during the forecast period, due to increasing cases of schizophrenia and rising demand for treatment for schizophrenia in the region. Growing geriatric population, advanced medical care, and early treatment capabilities aid in the expansion of the market in North America. Rising population and increasing cases of mental illness in countries such as Singapore, Japan, and Hong Kong are anticipated to drive the market in Asia Pacific in the coming years.
Segments
The global schizophrenia market has been segmented on the basis ofTypes
- Catatonic Schizophrenia
- Paranoid Schizophrenia
- Undifferentiated Schizophrenia
- Hebephrenic Schizophrenia
- Residual Schizophrenia
- Others
- Physical Examination
- Psychiatric Evaluation
- Tests & Screenings
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Third-generation Antipsychotics
- Psychotherapies
- Other Therapeutic Drugs
- Injectables
- Oral
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Johnson & Johnson Services, Inc.
- Karuna Therapeutics
- Bristol-Myers Squibb Company
- AstraZeneca
- Otsuka Holdings Co., Ltd.
- Alkermes
- Eli Lilly and Company
- Pfizer, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Mayo Foundation for Medical Education and Research (MFMER)
- Allergan, Plc
- Novartis AG
- PsychoGenics, Inc.
- Merz Pharma GmbH & Co.
- Others
Competitive Landscape
The schizophrenia market is competitive with the presence of key players such as Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; Mayo Foundation for Medical Education and Research (MFMER); Allergan, Plc; Novartis AG; PsychoGenics, Inc.; Merz Pharma GmbH & Co.; and others, who use strategies such as product launches, mergers, collaborations, partnerships, and acquisitions to strengthen their hold on the market. For example, in June 2020, announced the positive outcome of meeting with the US Food and Drug Administration (FDA) for its product KarXT, which works as an Acute Psychosis treatment for patients suffering from schizophrenia. In November 2020, Johnson & Johnson Services, Inc. submitted a supplemental new drug application for paliperidone palmitate to the US FDA.
Frequently Asked Questions
Johnson & Johnson Services, Inc.; Karuna Therapeutics; Bristol-Myers Squibb Company; AstraZeneca; Otsuka Holdings Co., Ltd.; Alkermes; Eli Lilly and Company; Pfizer, Inc.; and Sumitomo Dainippon Pharma Co. are some of the key players in the market.
North America dominates the global schizophrenia market.
Schizophrenia is considered as a chronic and serious mental disorder in which individuals interpret reality in abnormal way.
Catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, and residual schizophrenia are some of the types of schizophrenia.
The global schizophrenia market size was valued at around USD 7,666 million in 2021 and is anticipated to reach around USD 11,056 million by 2030.
The market is estimated to register CAGR of around 4.1% during the forecast period.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Schizophrenia Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Schizophrenia Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Schizophrenia Market - Supply Chain
4.5. Global Schizophrenia Market Forecast
4.5.1. Schizophrenia Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Schizophrenia Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Schizophrenia Market Absolute $ Opportunity
5. Global Schizophrenia Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Schizophrenia Market Size and Volume Forecast by Types
5.3.1. Catatonic Schizophrenia
5.3.2. Paranoid Schizophrenia
5.3.3. Undifferentiated Schizophrenia
5.3.4. Hebephrenic Schizophrenia
5.3.5. Residual Schizophrenia
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Schizophrenia Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Schizophrenia Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Schizophrenia Demand Share Forecast, 2019-2026
7. North America Schizophrenia Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Schizophrenia Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Schizophrenia Market Size and Volume Forecast by Types
7.4.1. Catatonic Schizophrenia
7.4.2. Paranoid Schizophrenia
7.4.3. Undifferentiated Schizophrenia
7.4.4. Hebephrenic Schizophrenia
7.4.5. Residual Schizophrenia
7.4.6. Others
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Schizophrenia Demand Share Forecast, 2019-2026
8. Latin America Schizophrenia Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Schizophrenia Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Schizophrenia Market Size and Volume Forecast by Types
8.4.1. Catatonic Schizophrenia
8.4.2. Paranoid Schizophrenia
8.4.3. Undifferentiated Schizophrenia
8.4.4. Hebephrenic Schizophrenia
8.4.5. Residual Schizophrenia
8.4.6. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Schizophrenia Demand Share Forecast, 2019-2026
9. Europe Schizophrenia Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Schizophrenia Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Schizophrenia Market Size and Volume Forecast by Types
9.4.1. Catatonic Schizophrenia
9.4.2. Paranoid Schizophrenia
9.4.3. Undifferentiated Schizophrenia
9.4.4. Hebephrenic Schizophrenia
9.4.5. Residual Schizophrenia
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Schizophrenia Demand Share Forecast, 2019-2026
10. Asia Pacific Schizophrenia Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Schizophrenia Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Schizophrenia Market Size and Volume Forecast by Types
10.4.1. Catatonic Schizophrenia
10.4.2. Paranoid Schizophrenia
10.4.3. Undifferentiated Schizophrenia
10.4.4. Hebephrenic Schizophrenia
10.4.5. Residual Schizophrenia
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Schizophrenia Demand Share Forecast, 2019-2026
11. Middle East & Africa Schizophrenia Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Schizophrenia Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Schizophrenia Market Size and Volume Forecast by Types
11.4.1. Catatonic Schizophrenia
11.4.2. Paranoid Schizophrenia
11.4.3. Undifferentiated Schizophrenia
11.4.4. Hebephrenic Schizophrenia
11.4.5. Residual Schizophrenia
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Schizophrenia Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Schizophrenia Market: Market Share Analysis
12.2. Schizophrenia Distributors and Customers
12.3. Schizophrenia Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Johnson & Johnson Services, Inc.
12.4.2. Karuna Therapeutics
12.4.3. Bristol-Myers Squibb Company
12.4.4. AstraZeneca
12.4.5. Otsuka Holdings Co., Ltd.
12.4.6. Alkermes
12.4.7. Eli Lilly and Company
12.4.8. Pfizer, Inc.
12.4.9. Sumitomo Dainippon Pharma Co., Ltd.
12.4.10. Mayo Foundation for Medical Education and Research (MFMER)&a
Methodology
Related Reports
Some other reports from this category!
Our Clients
